India, Oct. 10 -- India's Contract Development and Manufacturing Organization (CDMO) space continues to draw investor interest as pharmaceutical companies expand their global manufacturing capabilities and service offerings.

Notably, generic drugs remain exempt from these tariffs, strengthening India's competitive position as a reliable and cost-efficient manufacturing hub. Analysts at ICICI Securities have identified several stocks in the CDMO segment that could deliver strong upside potential of up to 50 percent from current levels.

1. Akums Drugs & Pharmaceuticals Ltd Incorporated in 2004, Akums Drugs & Pharmaceuticals is a leading contract development and manufacturing organization offering a broad range of pharmaceutical products a...